Fulgent Genetics (FLGT) is giving a booster shot with his big earnings upside, although the stock is well down from its highs as the market heads lower. The stock is up substantially after reporting huge Q4 earnings last night. FGLT has rapidly ascended to become one of the top providers of coronavirus testing in the country. It currently can process more than 60,000 tests per day. Throughout the pandemic, the company has been seeing a huge increase in demand.FLGT caught our attention in recent months owing to some massive guidance increases. On November 9, FLGT upped its full year guidance from $135 minimum to $235 minimum, then it rapidly increased that to over $300 minimum. The final 2020 revenue number was $421.7, min and the company’s guidance for 2021 amounts to $800 minimum. It is plain to see that even Fulgent has had some issues keeping up with its soaring revenue targets. Everyone was anticipating large Q4 numbers from Fulgent, but not this big: EPS of $6.20 in opposition to the consensus expectation of $4.05 and revenue of $295 minimum in opposition to the $199 minimum consensus expectation. FLGT also led Q1 ($325+ min) and FY21 revenue well over expectations.